NAARDEN, the Netherlands and MIAMI, April 09, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or œNewAmsterdam or the œCompany), a late-stage, clinical biopharmaceutical...
NewAmsterdam #Doses First Patient in Phase 3 Evaluating Obicetrapib & Ezetimibe
-- Observed reductions of 11% and 12% in 24- and 27-hydroxycholesterol in cerebrospinal fluid (œCSF), respectively, indicating potential improvement of cholesterol metabolism in the brain -- --...
Obicetrapib as a treatment for reducing cholesterol levels has potential to be the first cholesteryl ester transfer protein (CETP) inhibitor to advance to clinical practice, data and analytics company GlobalData has reported. This forecast is based on positive data from NewAmsterdam Pharma’s Phase II ROSE2 trial evaluating obicetrapib in combination with ezetimibe as an adjunct to high-intensity statin therapy.
Achieved Primary Endpoint with Statistically Significant 45.8% Median Reduction in LDL-C (p < 0.0001) in patients treated with 10mg obicetrapib-- -- 29.7% Median Reduction in Apo B and 37.0%...
Met Primary Endpoint with 63.4% Median Reduction in LDL-C (p<0.0001) – – 87.1% of Patients Treated with Combination of Obicetrapib and Ezetimibe Met Guideline-Recommended LDL-C Goal of <55...
NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia
A Dutch biotech loaded with hundreds of millions of dollars to resurrect an old Amgen drug has touted another mid-stage win for the cholesterol-lowering asset, and it will add another Phase III trial to the lineup.
NAARDEN, Netherlands & MIAMI--(BUSINESS WIRE)--NewAmsterdam Pharma, a clinical-stage company focused on the research and development of transformative oral therapies for metabolic diseases, today announced that it has initiated a Phase 2 dose-finding study of obicetrapib as an adjunct to stable statin therapy in Japanese patients with dyslipidemia. Obicetrapib is NewAmsterdam Pharma’s next-generation oral, low-dose and once-daily cholesteryl ester transfer protein (CETP) inhibitor, initially in development for patients at high risk for cardiovascular disease as an adjunct to maximally tolerated statin therapy, both as a monotherapy and in a fixed-dose combination with ezetimibe.
NewAmsterdam Pharma Announces Publication in Nature Medicine